Ozempic and Gastroparesis: What the Evidence Says About Risk

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Guidance to Specific Pharmacovigilance

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may wonder whether the medication could be causing gastroparesis—a condition where stomach emptying is delayed. While general health guidance has long emphasized broad medication safety, the growing use of GLP-1 receptor agonists like Ozempic calls for a closer look at specific gastrointestinal risks. This page reviews the available evidence on the potential association between Ozempic and gastroparesis, including labeling information and pharmacovigilance data.

Understanding Gastroparesis and Ozempic's Mechanism

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests, and management focuses on dietary modifications, prokinetic agents, and antiemetics. The condition can significantly impair quality of life and may be idiopathic or secondary to diabetes, surgery, or medications. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Its pharmacology includes slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions. The prescribing information for Ozempic documents that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo in placebo-controlled trials (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Clinical Trial Evidence and Reported Symptoms

In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions reported with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as an adverse reaction in these data, the mechanistic pathway linking Ozempic to gastroparesis is biologically plausible. GLP-1 receptor agonists delay gastric emptying via vagal and enteric nervous system pathways, and prolonged or severe delay can mimic or exacerbate gastroparesis. The reported symptoms—nausea, vomiting, dyspepsia, and gastroesophageal reflux—overlap with gastroparesis presentation, raising the question of whether Ozempic can induce a gastroparesis-like syndrome or unmask latent gastroparesis.

Risk Considerations and Adequacy of Warnings

Regarding risk considerations, the adequacy of warnings for Ozempic and gastroparesis is a key concern. The prescribing information does not include a specific warning for gastroparesis, but it does caution about gastrointestinal adverse reactions and advises monitoring. For patients who develop persistent or severe gastrointestinal symptoms, the label recommends considering dose reduction or discontinuation. However, the absence of a dedicated gastroparesis warning may leave some patients and clinicians unaware of the potential for this serious complication. Causation considerations for affected patients require careful evaluation. The timeline between exposure and documented harm is critical: gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis may develop later or persist after drug cessation. Patients with pre-existing gastroparesis or diabetic gastropathy may be at higher risk, and the drug's effect on gastric emptying could worsen their condition. For patients who experience severe symptoms, diagnostic workup for gastroparesis should be considered, and discontinuation of Ozempic may be necessary.

Conclusion: Balancing Evidence and Clinical Vigilance

In summary, while Ozempic is not explicitly labeled as causing gastroparesis, its pharmacological effect of delaying gastric emptying and the high incidence of gastrointestinal adverse reactions provide a mechanistic basis for concern. The evidence from clinical trials shows a dose-dependent increase in gastrointestinal symptoms, including dyspepsia and gastroesophageal reflux, which are consistent with gastroparesis. The adequacy of current warnings is limited, as gastroparesis is not specifically addressed. Patients who develop persistent nausea, vomiting, or abdominal pain while on Ozempic should be evaluated for gastroparesis, and clinicians should consider the drug's role in symptom causation. Further research is needed to clarify the incidence and risk factors for Ozempic-associated gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Ozempic cause gastroparesis?

While Ozempic is not explicitly labeled as causing gastroparesis, its pharmacological effect of delaying gastric emptying and the high incidence of gastrointestinal adverse reactions provide a mechanistic basis for concern. Clinical trials show a dose-dependent increase in symptoms like dyspepsia and gastroesophageal reflux, which overlap with gastroparesis presentation. Patients who develop persistent gastrointestinal symptoms should be evaluated for gastroparesis.

What are the symptoms of gastroparesis related to Ozempic?

Symptoms include nausea, vomiting, early satiety, bloating, and abdominal pain. These overlap with common gastrointestinal adverse reactions reported with Ozempic, such as dyspepsia, gastroesophageal reflux, and gastritis. If symptoms are persistent or severe, a diagnostic workup for gastroparesis should be considered.

Does the Ozempic label warn about gastroparesis?

The prescribing information does not include a specific warning for gastroparesis, but it cautions about gastrointestinal adverse reactions and advises monitoring. For persistent or severe symptoms, dose reduction or discontinuation is recommended. The absence of a dedicated gastroparesis warning may limit awareness among patients and clinicians.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.